FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma

Season 7 Episode 44  ·  Nov 03, 2022, 06:00 PM

Headliner
Share
Subscribe

Dr Goyal discusses the FDA approval of futibatinib in FGFR2-positive cholangiocarcinoma, key safety data from the FOENIX*-CCA2 trial, and the importance of biomarker testing in the cholangiocarcinoma population.

Share
Subscribe
Next
Sauter and Hill Talk Through CAR T Cell Sequencing and Access in Lymphomas
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air